Transgenic mice containing novel oncogene HCCR-2 were generated to analyse the phenotype and to characterize the role of HCCR-2 in cellular events. Mice transgenic for HCCR-2 developed breast cancers and metastasis. The level of p53 in HCCR-2 transgenic mice was elevated in most tissues including breast, brain, heart, lung, liver, stomach, kidney, spleen, and lymph node. We examined whether stabilized p53 is functional in HCCR-2 transgenic mice. Defective induction of p53 responsive genes including p21 WAF1 , MDM2, and bax indicates that stabilized p53 in HCCR-2 transgenic mice exists in an inactive form. These results suggest that HCCR-2 represents an oncoprotein that is related to breast cancer development and regulation of the p53 tumor suppressor.
Tumorigenesis in human and laboratory animals is a complex, multistep process (Nowell, 1976) . Transformation of rat embryo fibroblasts was not induced by either the Ras or Myc oncogenes when introduced alone, but was induced when the two were introduced together (Land et al., 1983; Birrer et al., 1988) . HCCR-2, a novel human cervical cancer oncogene, is overexpressed in various human cancers, and probably functions as a negative regulator of the p53 tumor suppressor (Ko et al., 2003) . Ectopic expression of HCCR-2 alone converts NIH/3T3 and Rat1 fibroblasts into a tumorigenic state, and nude mice injected with NIH/3T3 cells stably transfected with HCCR-2 form tumors that display the characteristics of an epithelial carcinoma (Ko et al., 2003) .
Although malignant transformation of human cells by a single oncogene may not occur or may require specialized factors, such as those found in a specific microenvironment, altered immune defense system, or specific genetic trait (Nebert, 1991) , we reasoned that activation of the single oncogene HCCR-2 can cause multiple human cancers. Several types of cancers such as chronic myeloid leukemia (Deininger et al., 1997) and Bcell lymphoma (Smith and Wickstrom, 1998) can be effectively treated by targeting only one of the multiple genetic anomalies that may have been responsible for tumorigenesis. To investigate whether forced expression of the novel oncogene HCCR-2 alone can induce tumorigenesis in vivo, we generated transgenic mice expressing the HCCR-2 gene under the cytomegalovirus (CMV) promoter (Figure 1 ). Of 15 transgenic mice generated, three male and two female transgenic founder mice were identified by Southern blot analysis using tail biopsy DNA. Tumors developed in 198 of 360 (55%) female transgenic offspring generated from these founder mice. Interestingly, these tumors, which developed with a mean latency period of 4 months (range 3-8 months), were only confined to the mammary fat pads. Approximately 50% of HCCR-2 transgenic mice with tumors showed metastases to contralateral mammary fat pads and the lung. Metastatic nodules were detected when the size of primary tumors reached 2 Â 2 cm. Penetrance of the neoplastic phenotype in parous mice was 100%. No tumors were detected in more than 100 non-transgenic control mice. These are confirmed by Southern blot analyses that were performed to eliminate the possibility of spontaneous origin tumors. No developmental abnormalities within transgenic mice were detected.
Histologically, all tumors showed papillary and glandular or duct-like structures. The tumor mass, measuring approximately 1.5 Â 1.5 cm, was noted in the right axillary area adjacent to the mammary fat pad. The tumor was a single, well-circumscribed nodule without a capsule. Histologic analysis revealed that tumor was a moderately differentiated intraepithelial neoplasia that exhibited characteristics resembling those of a human moderately differentiated ductal papillary adenocarcinoma detected (Figure 2a) . A tumor mass present near the breast tissue exhibited a solid and cystic appearance with hemorrhage ( Figure 2b ). Ductal carcinoma exhibited glandular differentiation with nuclear hyperchromatism and numerous mitosis (Figure 2c ). Multiple metastatic nodules were present in the entire lung parenchyma, and metastatic pulmonary tumor cells showed glandular differentiation similar to primary breast carcinoma (Figure 2d ). Several pulmonary venous structures were filled with tumor emboli and a tumor embolus was present in the congested vein ( Figure 2e ). Electron microscopy showed that tumor cells were connected by desmosomes ( Figure 2f) .
A number of genes are amplified and/or overexpressed in human mammary tumors. These include growth factors, such as molecule (int2) (Gordon et al., 1980) , growth factor receptors (epidermal growth factor receptor and c-ErbB2) (Miki et al., 1989) , tyrosine kinases (Schuuring et al., 1992) , transcription factors (cMyc) (Slamon et al., 1989) , and cell cycle regulators (cyclin D1/PRAD-1 and CDC25B) (Ottenhoff-Kalff et al., 1992) . Although a number of genes have been implicated in breast cancer development, few have been demonstrated to play important roles in mammary tumor formation (Berns et al., 1992) . A number of mouse systems also exist (Galaktionov et al., 1995) for study of the relevance of these mutations (gain of function mutations in proto-oncogenes and loss of function mutations in tumor-suppressor genes) in the pathogenesis of breast cancer, including transgenic mice expressing high levels of a specific gene in target tissues and knockout mice in which specific genes have been deleted via homologous recombination. Mice transgenic for HCCR-2 developed mammary fat pad tumors. This animal model provides an opportunity to study various aspects of the pathogenesis or treatment of breast cancer. In this regard, the HCCR-2 transgenic model is unique in that it consistently produced tumors with characteristics that resemble human breast adenocarcinomas. This model should, therefore, serve as a system for study of the mechanisms responsible for genetic HCCR-2 cDNA (filled box), and bovine growth hormone (bGH) polyA (hatched box). Transgenic mice expressing HCCR-2 were generated by conventional techniques as described (Proux et al., 1996) . Briefly, the complete HCCR-2 cDNA sequence was excised as a SalI fragment from plasmid pCEV 27 (Byrne et al., 1995) , and inserted as a SalI fragment into the XhoI site of the transgene expression vector pcDNA3 (Invitrogen). pcDNA3 was then digested with XmnI and SalI to generate a 3.6-kb fragment containing the HCCR-2 cDNA. Transgenic mice were generated by microinjection of HCCR-2 into the pronuclei of fertilized one-cell eggs. The HCCR-2 cDNA fragment (4 ng/ml) was microinjected into murine embryos of the FVB/N strain of mice (Jackson Laboratory, Bar Harbor, ME, USA). All microinjected embryos were implanted into pseudopregnant ICR strain of female mice (Jackson Laboratory). Genomic DNAs from the tail tips of offspring were isolated and subjected to PCR analysis with primers specific to HCCR-2 to determine offspring expressing the transgene. The oligonucleotides used for the amplification reactions were forward, 5 0 -GGGAGATGGAGCATTTGAGA-3 0 , and reverse, 5
0 -GCTTCCGGAAAGCATGATAG-3 0 . The predicted HCCR-2 product size was 198 bp. To confirm the specificity of the PCR reaction, Southern blot hybridization was performed on extracted genomic DNAs using 32 P-radiolabelled PCR product as a probe. All animal experiments were carried out in accordance with the Guidelines for Animal Experimentation and under the admission of Institutional Animal Care and Use Committee (IACUC) (f) Electron microscopy of a representative tumor nodule from the mammary fat pad of a HCCR-2 transgenic mouse. For transmission electron microscopy, tumors isolated from transgenic mice were fixed with mixture of 2% paraformaldehyde and 2.5% glutaraldehyde (Merck & Co., Inc., Rahway, NJ, USA) in 0.2 M phosphate buffer (pH 7.4) for 4 h at 41C, and then with 1% osmium tetroxide for 1 h at 41C. Specimens were sequentially dehydrated in a graded series of ethanol and embedded in Epon 812 (Sambrook et al., 1989) . Ultrathin sections (50-70 nm thick) were stained with uranyl acetate and lead citrate (Sambrook et al., 1989) and photographed with a transmission electron microscope (JEOL 1200 EX; Tokyo, Japan). Cytoplasm is filled with mitochondria and many vesiculated rough endoplasmic reticulais (arrow; higher magnification, left inset). Some desmosomes are also evident (arrowhead; higher magnification, right inset). Scale bar, 2 mm. In higher magnifications, the scale bar ¼ 0.5 mm Breast cancer development by HCCR-2 J Ko et al instability and may help identify factors that promote breast tumor progression and metastasis. Because HCCR-2 transgenic mice only developed tumors in the mammary fat pad, we are currently developing new transgenic animals for expression of HCCR-2 in other tumor types using regulated, high-level gene expression Tet-off and Tet-on systems (Dickson et al., 2000) .
We have reported that the p53 tumor suppressor is stabilized in HCCR-2 overexpressed RKO and NCI-H460 cells without genetic mutation and this event is correlated with functional impairment as indicated by defective induction of p53-dependent p21 WAF1 , MDM2, and bax, suggesting that HCCR-2 probably functions as a negative regulator of the p53 tumor suppressor (Ko et al., 2003) . Therefore, we examined whether p53 expression is affected in HCCR-2 transgenic mice. Results from Western blot analyses indicate that p53 expression levels of mammary fat pad tumors in HCCR-2 transgenic mice markedly increased compared with p53 expression levels of the mammary fat pad in transgenic mice without tumors or non-transgenic mice (Figure 3a) . p53 stabilization in HCCR-2 transgenic mice occurred more dramatically in metastatic breast tumors. We also examined whether stabilized p53 is functional in tumorous and non-tumorous mammary fat pads of HCCR-2 transgenic mice. Expression levels of p53 responsive genes including p21 WAF1 , MDM2, and bax were determined in tumorous and non-tumorous mammary fat pads of HCCR-2 transgenic mice. Our results show that the levels of p21 WAF1 , MDM2, and bax decreased in tumorous mammary fat pads and metastastic tumors of HCCR-2 transgenic mice, although the level of p53 was elevated in the tumor tissue (Figure 3a) . These indicate that an increased level of p53 in HCCR-2 transgenic mice did not induce expression of these proteins, but did cause down-regulated induction of these proteins. Taken together, stabilized p53 in HCCR-2 transgenic mice probably exists in an inactive form and overexpression of HCCR-2 induces the posttranslational modification of p53, which causes inhibition of proteasomal degradation and loss of the transcriptional activity of p53.
We next examined p53 expression levels in other internal organs of HCCR-2 transgenic mice. Levels of p53 and HCCR-2 were elevated in all tissues of HCCR-2 transgenic mice examined (Figure 3b ). These results are consistent with our previous report that HCCR-2 stabilizes the p53 tumor suppressor (Ko et al., 2003) . We also examined whether stabilized p53 is functional in other organ tissues of HCCR-2 transgenic mice. The results show that the levels of p21 WAF1 , MDM2, and bax decreased in most organ tissues of HCCR-2 transgenic mice or were unchanged in several tissues, although the level of p53 increased in all tissues of HCCR-2 transgenic mice (Figure 3b) . Therefore, p53 proteins that are expressed in non-tumor generating tissues are nonfunctional, as are the p53 proteins of mammary fat pads. The reason why only mammary fat pads produce tumors is not known. We are now investigating the mechanism of tissue specific regulation by HCCR-2. However, specific tumor production in mammary fat pads of HCCR-2 transgenic mice is probably related to female hormone exposure. Our preliminary data indicate that transgenic mice experiencing pregnancy can produce tumors much more effectively, indicating that estrogen exposure influences the incidence of mammary cancer development in these mice. This possibility is under investigation. Comparison of p53, HCCR-2, and p53 responsive protein expression in HCCR-2 transgenic mice tissues and their corresponding normal counterparts was examined by Western blot analysis. Freshly isolated normal and tumor mammary fat pad tissues (a), and other different tissues (b) were lysed in Laemmli sample buffer (Kim et al., 1996) . Equivalent volumes of cell lysates containing 20 mg total protein were loaded on 10% SDSpolyacrylamide gels and the proteins were separated by electrophoresis. Tissues from mice were mechanically dissociated with crossed scalpels, and were lysed with lysis buffer (20 mM HEPES, pH 7.4, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 3 mM EDTA, and protease inhibitors cocktail). For tissues extraction, it was homogenized in lysis buffer and the homogenate was clarified by centrifugation at 5000 g for 10 min. The supernatant was used for experiment. The proteins were then electroblotted to nitrocellulose membranes. The blots were incubated with polyclonal p53, p21 WAF1 , MDM2, bax antibodies, and polyclonal HCCR-2 antibody generated against fusion protein consisting of the C-terminal portion of HCCR-2, and developed with the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech., Piscataway, NJ, USA). The membrane was stripped and reprobed with b-actin antibody as an internal control
We have managed to convert mouse and human cells into tumor cells by delivering HCCR-2 alone without combination with other oncogenes. Our data suggest that HCCR-2 is probably activated as a potent oncogene in the development of human breast cancer. We suggest that HCCR-2 probably functions as a new oncogene for development of breast cancer.
